Aspirant Academy

MCQ

Qdenga clinical evidence MCQ - Practice Questions with Answers

Solve 1 Qdenga clinical evidence questions for RAS/RPSC preparation.

Practice questions

Q1Consider the following statements regarding the evidence and schedule for Qdenga: 1. Its recommended schedule consists of three 0.5 mL doses given at months 0, 3 and 6. 2. Its evaluation included an Indian phase-III safety and immunogenicity study among people aged 4 to 60 years. Which of the statements given above is/are correct?

A 1 only
B 2 only
C Both 1 and 2
D Neither 1 nor 2
Explanation

Statement 1 is incorrect because the recommended schedule has two 0.5 mL doses at months 0 and 3. Statement 2 is correct: the evaluation included an Indian phase-III study of safety and immunogenicity in the 4-to-60-year age group.

You've seen 1 of 1 sample questions

Unlimited practice on Qdenga clinical evidence comes with the RAS Test Series + Practice pack or Gate Pass.

More topics in Science & Technology

Explore other subjects